Clinical applications of next generation sequencing in breast cancer reveal diagnostic and prognostic potential, suggesting advances for treatment decisions.
Introduction Breast cancer is a heterogeneous disease that claims 670,000 lives by 2022. Omic technologies, particularly next generation sequencing (NGS) offers promising avenues for precision medicine. American Society of Clinical Oncology (ASCO) outlines genomic testing's utility, emphasizing prognostic and diagnostic potential.
No takes yet. Share an insight, caveat, or question.
Zuhdi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Annals of Medicine